Aug 20 2026 12:51 AM EST

Clinical Breakthroughs, AI Ambitions and Legal Risks Define Biggest Stock Moves

Copart, Inc. (NASDAQ: CPRT), Merck & Co., Inc. (NYSE: MRK), and SK Telecom Co., Ltd. (NYSE: SKM) led the market higher over the past five trading days, posting gains of 16.8%, 14.5%, and 18.7%, respectively, as investors responded to strong earnings, clinical advances, and visible growth in artificial intelligence infrastructure. In contrast, Tapestry, Inc. (NYSE: TPR) and Summit Therapeutics Inc. (NASDAQ: SMMT) fell sharply, down 20.6% and 15.4%, as company-specific setbacks and broader sector caution drove a rotation out of perceived risk.

The most significant upside moves were underpinned by tangible developments: Merck surged after reporting positive interim data from a Phase 3 trial of its mRNA melanoma vaccine in partnership with Moderna, alongside robust quarterly results and raised guidance. Copart rallied on the back of technical buying, institutional interest, and its fortress balance sheet, while SK Telecom was re-rated as investors digested the strategic pivot toward AI data centers, cybersecurity, and dividend growth. On the downside, Tapestry was weighed by litigation over outlet pricing, portfolio concentration, and a failed merger, while Summit Therapeutics was hit by a key clinical trial miss in oncology, heightening concerns about cash burn and dilution risk.

Clinical and Digital Innovation Power Top Performers

Merck’s 14.5% five-day rally was driven by interim results from a personalized mRNA cancer vaccine trial for melanoma, conducted with Moderna. The combination of the new vaccine with Keytruda reduced recurrence and distant metastasis rates versus Keytruda alone, prompting analyst upgrades and recalibrated expectations for peak sales in the multi-billion-dollar range. This breakthrough was reinforced by a strong operating performance—second-quarter revenue reached $17.4 billion (9% year-over-year growth), net income was $4.2 billion (13% growth), and Merck raised its full-year revenue guidance to $59–$61 billion. Institutional investors and analysts responded positively to the company’s pipeline progress, aggressive R&D investment ($15.8 billion in the past year), and capital returns, including a new $8 billion share repurchase program and a 5% dividend increase.

SK Telecom shares rose 18.7% as the company’s strategic focus on AI infrastructure and data center growth gained traction. Revenue from AI data centers grew 92.5% year-on-year to KRW 136.2 billion in the second quarter, while operating profit and net income surged 67.3% and 459.8%, respectively. Investors appeared to reward the company’s balance of high capex for AI expansion with robust free cash flow and dividend growth, setting SK Telecom apart from global telco peers. Partnerships with NVIDIA and Arm, combined with successful internationalization efforts and a defensive market share in 5G and broadband, reinforced the investment case.

Copart’s 16.8% rally reflected renewed interest in companies with strong technical momentum, cash-rich balance sheets, and sector resilience. The company reported $4.2 billion in cash, zero net debt, and nearly $1 billion in levered free cash flow, while maintaining gross margins of 45.5% and net income margins of 33.5%. Institutional positioning, share repurchases, and management changes further supported sentiment, with speculation around strategic M&A adding to the positive outlook. Macro trends—such as rising repair costs, EV adoption, and regulatory-driven complexity in the auto market—also provided underlying support.

Legal, Portfolio and Clinical Headwinds Pressure Laggards

On the downside, Tapestry fell 20.6% after a class action lawsuit targeting its Kate Spade Outlet pricing and ongoing fallout from the failed $8.5 billion Capri Holdings merger raised legal and operational uncertainty. The company’s strong top-line growth—full-year net sales of $8,004.2 million and a 14% year-over-year gain—was overshadowed by concerns about portfolio concentration, as Coach now contributes nearly 89% of revenue. Weakness at Kate Spade (7% Q4 sales decline) and the divestiture of Stuart Weitzman (-93.2% sales year-over-year) highlighted risks to growth diversification, while the accessible luxury segment faced macro headwinds and evolving consumer preferences.

Summit Therapeutics declined 15.4% after its pivotal Phase 3 trial of ivonescimab in non-small cell lung cancer failed to meet the primary endpoint of progression-free survival. The sell-off reflected both immediate disappointment and broader investor wariness toward clinical-stage biotechs without commercial products. Summit’s quarterly net loss reached $215.7 million on operating expenses of $220.5 million, with a trailing twelve-month net income margin of -256.3%. Though cash reserves stood at $690.7 million, the risk of dilution and the need for positive regulatory milestones—such as the upcoming FDA PDUFA date in November—remained front of mind for investors. The broader risk-off sentiment in small-cap biotech, driven by rising rates and a shift away from unprofitable growth, further amplified the move.

Fundamental Catalysts and Risk Differentiation in Focus

The market action of the past week highlighted a clear bifurcation between companies with demonstrated earnings power, pipeline catalysts, and disciplined capital allocation, and those exposed to legal, clinical, or concentration risks. Investors favored companies delivering visible progress in innovation and margin expansion—whether through clinical trial data, technological infrastructure, or balance sheet strength—while showing less tolerance for companies where setbacks exposed future uncertainty or operational fragility.

Looking ahead, the persistence of these moves will likely depend on the follow-through of clinical milestones, regulatory clarity, and continued execution on strategic pivots. For outperformers, the challenge will be to sustain growth and deliver on elevated expectations, while underperformers face the need for credible catalysts and risk mitigation to rebuild confidence. The period underscores the market’s renewed emphasis on fundamental catalysts and the premium placed on resilience amid sector and macroeconomic crosscurrents.